Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined the role of MEK signaling pathway inhibition in head and neck squamous cell carcinoma (HNSCC) both in vitr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Kang, Seong-Ho, Keam, Bhumsuk, Ahn, Yong-Oon, Park, Ha-Ram, Kim, Miso, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287796/
https://ncbi.nlm.nih.gov/pubmed/30546955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1515057
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars